Governance How to Join Meetings and Events Reports Funding Opportunities
THE IUPHAR GI Section (email@example.com)
During the past 3 decades, the discovery and development of successful GI drugs have revolutionized the treatment of peptic ulcers by remarkably reducing the need for surgical intervention; including the histamine (H2) receptor antagonists and proton pump inhibitors (PPIs). Subsequently, the discovery of association of H. pylori with gastritis and peptic ulcer development has led the use of antibiotic regimens in conjunction with H2 antagonists and PPIs as an even more effective means for peptic ulcer treatment.
The IUPHAR GI Section was established in 1994. During the past 20 years, numerous symposia have been successfully organized to exchange original ideas and preliminary results among the members. Several Nobel laureates have taken part in, including James Black, Barry Marshall, Robin Warren, and Robert J. Lefkowitz.
The primary objective of the IUPHAR GI Section is to provide the state-of-the-art of GI pharmacology regarding the properties and actions of new drugs as well as the new properties and new actions of old drugs for GI diseases, e.g. nonsteroidal anti-inflammatory drugs (NSADS)-induced GI mucosal damage, gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), GI cancers and obesity.
The specific objectives:
1. Promoting basic and clinical pharmacology research and education by frequently organizing scientific symposia
2. Promoting international collaborations by planning and coordinating research programs
3. Providing consultancy and drug testing services for pharmaceutical companies
If you have registered in myIUPHAR under the Members tab then you may join the Gastrointestinal Pharmacology Discussion Group.